臨床神経学

<シンポジウム32―3>神経疾患に対する抗体療法

アルツハイマー病に対する抗体療法

田平 武, 松本 信英, 金 海峰

順天堂大学大学院医学研究科認知症診断・予防・治療学〔〒113―0033 東京都文京区本郷2―11―5 第2谷口ビル3階〕

In order to avoid Abeta-induced autoimmune encephalitis, several monoclonal and polyclonal antibodies are in clinical trials. These are bapineuzumab, solanezumab, ponezumab, gantenerumab, BAN2401, gammaguard and octagam. Since each antibody has a different antigen epitope of Abeta, anti-amyloid activities are different. It is unknown which antibody is effective for Alzheimer disease, and we must wait for the result of clinical trials. Some patients who developed tissue amyloid plaque immuno-reactive (TAPIR) antibody showed slower decline after AN-1792 vaccination. We developed TAPIR-like monoclonal antibody, which was found to react with Abeta oligomers preferentially.
Full Text of this Article in Japanese PDF (146K)

(臨床神経, 51:1160−1161, 2011)
key words:アルツハイマー病,抗体,ワクチン

(受付日:2011年5月20日)